I am reading the trial table rather than the press release, which is why the numbers differ.
I want to understand what this actually establishes, as opposed to what it is being used to imply.
My concern is that I am being invited to draw a conclusion the data does not support.
What is the correct interpretation, and what is the common misreading?
Answering this needs the eGFR entry criteria of the trial you are quoting, because renal trials enrol by kidney function and the results do not transfer across strata.
FLOW randomised people with type 2 diabetes and chronic kidney disease to semaglutide and reported roughly a twenty-four per cent reduction in the primary kidney composite, which combined kidney failure, sustained large eGFR decline and death from kidney or cardiovascular causes.
| Quantity | Value | Derivation |
|---|---|---|
| Control-arm event rate | 8.0 % | From the trial table, not the abstract |
| Hazard ratio | 0.80 | Reported |
| Treated event rate | 6.4 % | 8.0 × 0.80 |
| Absolute risk reduction | 1.6 pp | 8.0 − 6.4 |
| Number needed to treat | 63 | 1 ÷ 0.016 |
| Relative risk reduction | 20 % | 1 − 0.80 |
The last two rows describe the same finding. Only one of them is used in headlines.
The relevant detail is that the initial eGFR dip is on the order of one to three millilitres per minute per 1.73 square metres and recovers. Reading it as harm and stopping is the error the pattern is designed to catch you with.
Cite FLOW for hard kidney endpoints, not a cardiovascular trial subgroup.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemAsk PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.